New data entry interface runs on top of existing software for accelerated navigation
New data entry interface runs on top of existing software for accelerated navigation
Oracle Corp. (Redwood Shores, CA) introduced Remote Data Capture Onsite, its next-generation EDC system data collection for clinical trial investigative sites. The interface is designed to accelerate and simplify the collection of clinical data and EDC deployment at investigative sites.
The new Oracle interface runs on top of its existing software product Oracle Remote Data Capture v4.5.1 for more intuitive data entry and navigation of CRFs. The interface allows site personnel to easily locate and update patient information and data entry, as well as add pages to the CRF. The system performs immediate online edit checks, which involves a discrepancy management module from the CRF to capture, route, and resolve discrepancies if applicable.
The Onsite interface features graphic icons that illustrate the status of CRF data. It also enables electronic messaging between users, CRF verifications as a group or individually, and backup approvals with e-signatures.
Oracle Corp., (650) 506-8920, www.oracle.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.